Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.08. | Aquaporin A/S: Aquaporin announces results for first half 2025 | 274 | PR Newswire | Company announcement No. 16/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngby aquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug. 21, 2025 /PRNewswire/... ► Artikel lesen | |
13.08. | AQUAPORIN A/S: Aquaporin to host half-year 2025 results webcast on August 21 | 3 | Cision News | ||
12.08. | Aquaporin Cuts FY Revenue Guidance, Initiates Strategic Review | 1 | RTTNews | ||
AQUAPORIN Aktie jetzt für 0€ handeln | |||||
11.08. | Aquaporin A/S: Aquaporin lowers revenue guidance for 2025, but maintains EBITDA guidance, and initiates strategic review | 1.028 | PR Newswire | Company announcementNo. 15/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug.... ► Artikel lesen | |
05.08. | Aquaporin A/S: Aquaporin successfully achieves up to 20% energy savings at Kranji NEWater Factory | 280 | PR Newswire | KONGENS LYNGBY, Denmark, Aug. 5, 2025 /PRNewswire/ -- Aquaporin has successfully completed the Living Lab Project to develop the world's first biomimetic low-energy Aquaporin Inside® CLEAR... ► Artikel lesen | |
08.07. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons discharging managerial responsibilities | 2 | Cision News | ||
07.07. | AQUAPORIN A/S: Aquaporin issues warrants under a new warrant program | 2 | Cision News | ||
20.06. | AQUAPORIN A/S: Major shareholder announcement | 2 | Cision News | ||
20.06. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons closely associated with persons discharging managerial responsibilities in Aquaporin | 2 | Cision News | ||
12.06. | Aquaporin A/S: Aquaporin appoints Chief Executive Officer | 393 | PR Newswire | Company announcementNo. 09/2025
Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark... ► Artikel lesen | |
21.05. | Aquaporin A/S: Aquaporin Q1 2025 Trading Statement - maintains full-year financial guidance for 2025 | 310 | PR Newswire | Company announcementNo. 08/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark , May 21, 2025 /PRNewswire/... ► Artikel lesen | |
15.05. | AQUAPORIN A/S: Aquaporin sells 500 CLEAR membranes to Chinese company CRZLO | 2 | Cision News | ||
08.05. | AQUAPORIN A/S: Aquaporin membranes to power projects in Chile and Mexico | 1 | Cision News | ||
01.05. | AQUAPORIN A/S: Aquaporin secures pilot plant contract for Trinity College Dublin at the IBF National Bioeconomy Campus | 5 | Cision News | ||
24.04. | Business transacted at the Annual General Meeting of Aquaporin A/S | 2 | Cision News | ||
11.04. | Aquaporin A/S - Admittance to trading and official listing of new shares due to exercise of warrants | 178 | GlobeNewswire | The share capital of Aquaporin A/S has been increased. The admittance of trading and official listing of new shares will take effect as per 14 April 2025 in the ISIN below.
ISIN:
DK0061555109
Name:
Aquaporin
Volume... ► Artikel lesen | |
20.03. | Aquaporin A/S: Aquaporin announces full-year 2024 results | 566 | PR Newswire | Company announcementNo. 03/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, March 20, 2025 /PRNewswire/... ► Artikel lesen | |
20.03. | Aquaporin A/S: Aquaporin announces guidance for 2025 | 142 | GlobeNewswire (Europe) | Company announcement
No. 02/2025
Inside information
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Kongens Lyngby, Denmark, March 20, 2025 -... ► Artikel lesen | |
26.02. | Aquaporin A/S: Aquaporin improves EBIT and specifies revenue guidance for 2024 | 137 | GlobeNewswire (Europe) | Company announcement
No. 01/2025
Inside information
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Kongens Lyngby, Denmark, February 26, 2025... ► Artikel lesen | |
14.11.24 | Aquaporin A/S: Aquaporin Q3 2024 Trading Statement | 564 | GlobeNewswire (Europe) | Company announcement
No. 19/2024
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Copenhagen, Denmark, November 14, 2024 - Aquaporin A/S (ticker:... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 37,440 | -0,48 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
EVOTEC | 6,138 | +1,12 % | adidas, Evotec, Gerresheimer, Hensoldt, TeamViewer, TUI - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
VALNEVA | 4,976 | +8,84 % | Valneva-Aktie dreht wieder auf - das ist der Grund | Die Aktie des europäischen Impfstoff-Entwicklers steigt am Dienstag auf den höchsten Stand seit dem Bekanntwerden des Entzugs der US-amerikanischen Zulassung für das Chikungunya-Vakzin Ixchiq im August.... ► Artikel lesen | |
BIONTECH | 83,15 | -0,60 % | BioNTech SE: BioNTech veranstaltet am 1. Oktober 2025 zweiten "AI Day" als eine Ausgabe der "Innovation Series" | MAINZ, Deutschland, 23. September 2025("InstaDeep"), am Dienstag, den 1. Oktober 2025 um 15:00 Uhr MESZ (09:00 Uhr EDT) ihren zweiten "AI Day" aus, eine Ausgabe von BioNTechs "Innovation Series"... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,825 | -1,83 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
TARSUS PHARMACEUTICALS | 58,14 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
MAZE THERAPEUTICS | 25,210 | 0,00 % | Maze Therapeutics, Inc.: Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria ... | Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 6,180 | -1,04 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
SIONNA THERAPEUTICS | 29,500 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis | WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen | |
ADMA BIOLOGICS | 14,530 | -1,16 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
MODERNA | 21,000 | -1,43 % | Moderna-Aktie: Kurs heute im Minus (21,2677 €) | Am US-amerikanischen Aktienmarkt liegt die Aktie von Moderna zur Stunde im Minus. Der jüngste Kurs betrug 24,79 US-Dollar. Eine Verbilligung in Höhe von 1,09 US-Dollar müssen derzeit die Aktionäre von... ► Artikel lesen | |
CRISPR THERAPEUTICS | 54,00 | -0,92 % | Morningstar Launches New Benchmark and Expands with CRSP Acquisition | ||
SCISPARC | 6,210 | +39,24 % | SciSparc Ltd: SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer | TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies... ► Artikel lesen | |
PRELUDE THERAPEUTICS | 1,340 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Prelude Therapeutics mit Kursziel von 5 $ | ||
VERA THERAPEUTICS | 29,400 | +1,73 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen |